Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG-1801 in B-Cell Lymphoma
NCT03804996Phase 1Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Mar 2019
- Primary completion
- Feb 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NI-1701 in B cell lymphoma (2 arms), sponsored by TG Therapeutics, Inc. Primary endpoints: Recommended Phase 2 Dose at 18 months and Safety Profile of TG-1801 at 18 months. Started Mar 2019; status: completed.
02
Drugs
NI-1701
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03804996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03804996.